Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Alberto FarolfiMicaela PetroneEmanuela ScarpiValentina GallàFilippo GrecoClaudia CasanovaLucia LongoGennaro CormioMichele OrdituraAlessandra BolognaLaura ZavalloneJole VentrigliaElisena FranzeseVera LoizziDonatella GiardinaEva PigozziRaffaella CioffiSandro PignataGiorgio GiordaUgo De GiorgiPublished in: Targeted oncology (2019)
Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII.